Inspire Medical Systems reported Q1 2026 revenue of $204.6 million on 4 May 2026, up 1.6% year over year, and beat consensus EPS at $0.10 against an expected loss of $0.28. The same release revised full-year guidance down to $825 million to $875 million, a 4% to 10% decline against 2025, and quantified the cause as a combined $120 million to $150 million adverse impact for FY26 from coding uncertainty and the Centers for Medicare and Medicaid Services’ new Wasteful and Inappropriate Service Reduction (WISeR) Model. Q1 alone took roughly $20 million of that hit. CEO Tim Herbert told analysts to expect a 9% to 11% year-over-year revenue decline in Q2. Six sell-side firms cut their price targets between 5 and 7 May.
In the same Calendar Year 2026 Medicare rules that put deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, phrenic nerve stimulation, hypoglossal nerve stimulation, and induced lesions of nerve tracts under AI-assisted prior authorization in six pilot states, CMS raised professional payment for NeuroPace’s responsive neurostimulation system by 43% for initial implants and 45% for replacements, and reassigned RNS replacement procedures to a hospital APC carrying 47% higher Medicare reimbursement. NeuroPace’s RNS for epilepsy is not on the WISeR services list. Two neuromodulation categories, two opposite directions, one rule cycle.
What WISeR covers
WISeR is a six-year CMS Innovation Center pilot running 1 January 2026 through 31 December 2031. Six states are in scope: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Original Medicare prior authorization requests began on 5 January 2026 for 17 outpatient services CMS classified as commonly overused or fraud-prone. The neuromodulation cohort inside the 17 includes Electrical Nerve Stimulators, Sacral Nerve Stimulation for Urinary Incontinence, Phrenic Nerve Stimulator, Deep Brain Stimulation for Essential Tremor and Parkinson’s, Vagus Nerve Stimulation, Induced Lesions of Nerve Tracts, and Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. Coverage decisions arrive within 72 hours, 48 expedited. AI-assisted clinical review flags cases; final adverse decisions are made by licensed clinicians. Contractor compensation is tied to a percentage of expenditures CMS deems averted as wasteful.
How it landed at Inspire
Hypoglossal nerve stimulation is Inspire’s only product line. The CPT code attached to roughly 10,000 Inspire V cases in 2025, CPT 64568, is no longer reimbursable for Medicare under the new rule. Medicare currently routes Inspire procedures through CPT 64582 as an interim. A new single-lead CPT code for the Inspire V system is expected to take effect on 1 January 2028. Layered on top of this coding transition, WISeR added prior authorization for HGNS in all six pilot states. The two pressures hit simultaneously and management collapsed them into one figure for FY26 disclosure.
Six analysts moved their price targets between 5 and 7 May. JPMorgan cut from $67 to $54 with a neutral rating. Wells Fargo cut from $70 to $56 at equal weight. Piper Sandler cut from $85 to $55. Robert W. Baird moved to $50 at neutral. Mizuho cut to $55 at outperform. Truist moved to $50 at hold. The cluster of resets at $50 to $56 represents a 30% to 35% downward repricing from where the cohort sat at the start of May.
Why Boston Scientific and Abbott did not disclose comparable drag
Boston Scientific reported Q1 2026 on 22 April with neuromodulation organic sales up 15%. The portfolio includes deep brain stimulation, which is in WISeR scope. No WISeR-specific drag was quantified on the call. Abbott reported the same day with medical devices up 12.4% organic and neuromodulation in double-digit territory. Abbott carries DBS and SCS, both of which sit inside WISeR-affected categories. Abbott did not quantify WISeR exposure either.
Inspire’s Medicare exposure is heavier than either of theirs, and HGNS is its only revenue line, with no DBS or SCS portfolio to absorb the disruption. The combination makes Inspire the publicly-traded canary on WISeR’s procedure-volume effect rather than an indicator of the wider neuromodulation sector’s exposure.
The NeuroPace contrast
NeuroPace reports Q1 2026 on 12 May. Its 2026 revenue guidance was reaffirmed at $98 million to $100 million earlier in the year, implying core RNS growth of 20% to 22%. The CY 2026 Medicare Physician Fee Schedule final rule increased professional payment for RNS implants by 43% and replacements by 45%. The CY 2026 Outpatient Prospective Payment System rule reassigned RNS replacement procedures from APC 5464 to APC 5465, a 47% lift in average hospital reimbursement. RNS for epilepsy was not added to the WISeR services list. Whatever logic drove CMS to compress one set of neuromodulation categories drove the agency in the opposite direction on another.
The BCI read-through
Commercial cortical BCI is not yet at CMS coverage. When it arrives, the codes attached to it will land on one side of this bifurcation or the other. Synchron, Neuralink, Paradromics, Precision Neuroscience, CorTec, and Epia Neuro are all building toward FDA approval in indications that will eventually require Medicare coverage decisions. The strategic question for any company in that cohort is whether their device class will be treated like Inspire’s HGNS, compressed via WISeR or its successor, or like NeuroPace’s RNS, categorically excluded from WISeR scope and boosted via OPPS and MPFS reassignment. The CMS Innovation Center has demonstrated that both moves are possible inside one rule cycle.
WISeR is a six-year pilot. CMS retains the option to expand the model, narrow it, gold-card consistent providers out of it, or roll its lessons into national policy. The Inspire data point is the start of public visibility into what AI-assisted prior auth does to neuromodulation procedure volumes in practice. The next data points come from NeuroPace on 12 May and Medtronic later in the month.
Sources: CMS WISeR Model overview. Inspire Q1 2026 release, 4 May 2026. Inspire Q1 2026 earnings call transcript via Benzinga. NeuroPace Medicare reimbursement increase release. AAO-HNS WISeR HGNS practice guide.